Background
==========

Rheumatoid arthritis (RA) is a chronic, systemic and progressive inflammatory disorder primarily characterized by persistent chronic synovitis, progressive erosions, and cartilage destruction, which may cause deformed and painful joints, even resulting in loss of function \[[@b1-medscimonit-22-316]\]. RA affects 0.5--1% adults in the developed world, with 5--50 per 100,000 people being newly diagnosed with the condition, annually. Furthermore, the onset of RA is most frequent in females and the elderly \[[@b2-medscimonit-22-316]\]. RA, without intervention, may eventually cause joint damage, disability, reduced quality of life, cardiovascular events and other comorbidities \[[@b3-medscimonit-22-316],[@b4-medscimonit-22-316]\]. Although a variety of environmental and behavioral factors confer a high risk of developing RA, genetic factors are suspected to account for up to 50% of the risk for developing RA \[[@b5-medscimonit-22-316]\].

Vascular endothelial growth factor (VEGF) is an important signaling protein and a secreted ligand released by cells to stimulate vasculogenesis and angiogenesis. VEGF plays an important role in regulating angiogenesis through promoting vascular endothelial cell growth, migration, and lumen formation \[[@b6-medscimonit-22-316]\]. In addition, VEGF is also capable of inducing proinflammatory change, seen in chronic inflammation, which involves leukocyte accumulation, collagen deposition, and blood vessel remodeling \[[@b7-medscimonit-22-316]\]. VEGF is also released by inflammatory cells and, in turn may represent the inflammatory component in many disease processes \[[@b8-medscimonit-22-316]\]. In this context, enhanced serum VEGF levels are associated with the duration and severity in many disorders, such as RA \[[@b9-medscimonit-22-316]\]. The human *VEGF* gene is localized on chromosome 6p12, and contains of 8 exons. The *VEGF* gene is also an independent risk factor for RA severity, and correlates with multiple disease parameters, such as disease activity, joint damage, and functional disability \[[@b10-medscimonit-22-316]\]. Two common single-nucleotide polymorphisms (SNPs), rs833070 (G\>A) located in intron 2 and rs3025030 (G\>C) located in intron 5, are suspected to result in altered protein expression of VEGF and have strong links to the onset of RA, although some studies dispute such a link \[[@b11-medscimonit-22-316]\]. Our present study evaluates the common SNPs in the *VEGFA* gene \[rs833070 (G\>A) and rs3025030 (G\>C)\] for their influences on the circulating levels of VEGF protein and their effects on disease activity and synovial lesions in RA.

Material and Methods
====================

Ethics statement
----------------

The study was approved by the Ethics Committee of the Zhujiang Hospital, Southern Medical University. The written informed consent was provided by each eligible patient and the study conformed to the Declaration of Helsinki \[[@b12-medscimonit-22-316]\].

Patients
--------

This study was conducted between October 2010 and May 2012 on a population of RA patients (n=98) from Zhujiang Hospital, Southern Medical University. Patients with RA who satisfied all aspects of the 2010 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) classification criteria for RA were recruited to the study \[[@b13-medscimonit-22-316]\]. There were 32 male and 66 female RA patients, with an age range of 18--80 years (mean age, 50.82±12.53 years) and mean disease duration of 3.0 years (range, 0.8--8.0 years). A group of 100 healthy volunteers (male, 35; female, 65; age range, 15--85 years; mean age, 48.67±13.41 years) were enrolled as the control group from the Medical Examination Center of the Shengjing Hospital of China Medical University. No statistical difference in age or sex existed between the RA group and the control group. Patients with systemic lupus erythematosus (SLE), Sjögren syndrome (SS), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), polymyositis (PM), dermatomyositis (DM), other autoimmune diseases, hereditary diseases, severe heart, lung, liver, or kidney dysfunction, benign or malignant tumors, or other related diseases were excluded from this study.

Clinical data collection
------------------------

General clinical data of all the study subjects such as age, sex, disease duration, present and past medical history, and the history of hereditary disease were collected and recorded. Common clinical laboratory parameters for RA including routine blood test, erythrocyte sedimentation rate (ESR), rheumatoid factor (RF) and acute C-reactive protein (CRP) were collected.

Detection of VEGF polymorphisms
-------------------------------

Morning fasting venous blood samples (2 ml) were collected from all subjects. EDTA was used as an anticoagulant for blood collection. Genomic DNA was extracted from the white blood cells (WBCs) collected from venous blood by using a DNA Extraction Kit (Tiangen Biotech, Beijing, China) according to the manufacturer's protocol. The SNP genotyping was conducted using the matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) (Sequenom Inc., San Diego, CA, USA) \[[@b14-medscimonit-22-316]\]. The primers ([Table 1](#t1-medscimonit-22-316){ref-type="table"}) were designed with MassARRAY^®^ Assay design 3.1 software, available with the MassARRAY SNP genotyping system (Sequenom, Inc., San Diego, CA, USA). The PCR reaction condition was: 45 cycles of predenaturation at 94ºC for 15 s, denaturation at 94ºC for 20 s, annealing at 56ºC for 30 s, and extension at 72ºC for 1 min, followed by a final extension at 72ºC for 3 min, and stored at 4ºC. SAP reaction solution was prepared and added into a 384-well plate containing PCR-amplified products to degrade dNTP at 37ºC for 20 min, then placed at 85ºC for 5 min to inactivate SAP, and stored at 4ºC. Next, the iPlex reaction system was prepared and added into the 384-well plate, and the single-base extension reaction was conducted under the following conditions: at 94ºC for 30 s, at 94ºC for 5 s, at 52ºC for 5 s, at 80ºC for 5 s, at 72ºC for 3 min, and storing at 4ºC. The purification of PCR products was performed by demineralization with resin. The DNA samples were transferred from the 384-well plate onto the MassARRAY SpectroCHIP covered with matrix, and detected with the mass spectrometer. The genotyping analysis was performed by using the MassARRAY^®^ TYPER software.

Enzyme-linked immunosorbent assay (ELISA)
-----------------------------------------

The serum concentrations of VEGF were measured by the ELISA method using an ELISA kit provided by Wuhan Boshide Company (Wuhan, China) in accordance with the manufacturer's instructions \[[@b15-medscimonit-22-316]\].

Disease activity score (DAS)
----------------------------

A total of 28 joints, including shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints of hands, and knee joints, were scored by DAS scoring system \[[@b16-medscimonit-22-316]\]. The number of swollen and tender joints in each RA patient was examined and recorded, and the DAS28 score was calculated by combining the ESR and self-evaluation in patients with RA. \[n1, the number of tender joints; n2, the number of swollen joints; n3, ESR (mm/h); n4, health evaluation in RA patients\]. The DAS28 score of \<2.6 is considered as remission, 2.6--3.2 as low mobility, 3.3--5.1 as moderate mobility, and \>5.1 as frequent mobility.

Ultrasonography
---------------

The ultrasonic examination was performed using a Siemens ACUSON S2000™ color Doppler (Siemens, Erlangen, Germany), with the probe frequency of 8--13 MHZ. The 28 joints of each RA patient were examined using direct contact method. All patients adopted the supine or sitting position, adjusted based on the examined joints, with the examined joint fully exposed. An experienced physician with ultrasound expertise, who did not know the disease status and treatment status of the patients, monitored the ultrasound examinations.

Ultrasonic examination
----------------------

Based on the classification standard of Walther, the synovial thickness was classified into 4 grades: grade I, no synovial hyperplasia and thickness \<2 mm; grade II, mild synovial hyperplasia and thickness=2--4 mm; grade III, moderate synovial hyperplasia and thickness=5--9 mm; grade IV, severe synovial hyperplasia and thickness \>9 mm \[[@b17-medscimonit-22-316]\]. Joint effusion in joint scotoma (anteroposterior diameter) was determined based on different joint size and position: knee suprapatellar bursa scotoma \>4 cm is considered as joint effusion; medial and lateral knee scotoma \>2 cm as joint effusion; scotoma of shoulder joins, elbow joints, and wrist joints, metacarpophalangeal and proximal interphalangeal joints \>2 cm as joint effusion.

Power Doppler evaluation
------------------------

The semi-quantitative signal of each point of synovium in the 28 joints was observed and classified: grade 0, no signal or blood flow; grade 1, slight signal, and single or independent vascular signals less than 3; grade 2, moderate fusion vessel, and more than 3 independent signals, or fusion signals less than half the synovial region; grade 3, significant signal, and visible vascular signals in more than half the medial region of the joints.

Recording items
---------------

Recording items consisted of the followings: (1) US joint count SH: the number of joints with thickened synovium; (2) US joint count SF: the number of joints with effusion; (3) US joint count PD: the number of joints with energy signals; (4) US index SH: total synovial thickening score, which was the sum of the synovial thickening score of the 28 joints; (5) US index SF: total joint effusion score, which was the sum of joint effusion score of the 28 joints; (6) total sharp scores (TSS): the sum of the highest power Doppler score of each joint.

Statistical analysis
--------------------

Statistical analysis was conducted using SPSS 18 software (SPSS Inc., Chicago, IL, USA), and the data are represented as means ± standard deviation (SD), median, or percentage. The statistical comparison between 2 groups was conducted using the *t*-test or the analysis of variance (ANOVA). Genotype distribution in the control group was tested by Hardy-Weinberg equilibrium (HWE). The differences in genotype and allele distribution between the RA group and the control group are represented as odds ratio (OR) and 95% confidence interval (CI). *P* values for all tests are 2-tailed, and \<0.05 was considered as statistically significant.

Results
=======

Characteristics of RA patients
------------------------------

[Table 2](#t2-medscimonit-22-316){ref-type="table"} shows the demographic and clinical characteristics of 198 subjects, consisting of 98 RA patients and 100 controls, from a hospital based population at the time of recruitment. Comparisons between the RA group and the control group demonstrated that ESR, RF, acute CRP, and serum VEGF levels were significantly higher in patients with RA than in controls (all *P*\<0.05). No statistical differences were seen in age, gender, WBC, red blood cell (RBC), hemoglobin (HGB) and platelet (PLT) count (all *P*\>0.05).

Distributions of *VEGF* SNPs
----------------------------

The genotype and allele frequencies of the *VEGF* genetic polymorphisms, rs833070 (G\>A) and rs3025030 (G\>C), in RA patients and controls are displayed in [Table 3](#t3-medscimonit-22-316){ref-type="table"}. Genotypes of *VEGF* rs833070 (G\>A) and rs3025030 (G\>C) in controls were distributed in accordance with HWE (all *P*\>0.05). The distributions of allele and genotype frequencies of the *VEGF* rs833070 (G\>A) in the RA group were significantly different from the control group (all *P*\<0.05). The *VEGF* rs833070 AA genotype and A allele frequency were significant higher in the RA group than in the control group (AA genotype frequency: 59.2% *vs.* 43.0%, *P\<*0.05; A allele frequency: 78.1% *vs.* 67.0%, *P\<*0.05). We detected that the polymorphisms located in rs833070 of the *VEGF* gene were strongly linked with an increased risk of RA (AA *vs.* GG + AG, OR=1.922, 95%CI=1.093--3.382, *P*=0.023; A *vs.* G, OR=1.752, 95%CI=1.119--2.745, *P*=0.014). Similarly, statistical differences in the distribution of genotypic and allele frequencies of *VEGF* rs3025030 (G\>C) were observed between the RA group and the control group (all *P*\<0.05). *VEGF* rs3025030 CC genotype frequency was 50.0% in RA patients *vs.* 67.0% in controls (*P*\<0.05). In addition, *VEGF* rs3025030 C allele frequency was 69.4% in RA patients and 81.0% in controls (*P\<*0.01). *VEGF* rs3025030 CC genotype might be related to a reduced risk of RA (CC *vs.* GC + GG, OR=0.473, 95%CI=0.266--0.840, *P*=0.010).

Comparison of serum *VEGF* levels
---------------------------------

[Figures 1](#f1-medscimonit-22-316){ref-type="fig"} and [2](#f2-medscimonit-22-316){ref-type="fig"} show the comparison of VEGF serum levels between different genotypes of rs833070 and rs3025030 in RA patients. The comparisons of serum levels of VEGF based on genotypes of rs833070 showed that the serum level of VEGF was significantly higher in RA patients with AA genotype (1737.5±250.3 pg/mL) compared to RA patients with GG genotype (623.7±183.6 pg/mL) and AG genotype (1030.2±107.9 pg/mL) (*P*\<0.01) ([Figure 1](#f1-medscimonit-22-316){ref-type="fig"}). Additionally, serum VEGF levels in RA patients with rs3025030 CC genotype were lower than in patients carrying the rs3025030 GC genotype and GG genotype (1232.94±358.39 *vs.* 1586.67±398.39 *vs.* 1812.37±309.07, *P*\<0.01) ([Figure 2](#f2-medscimonit-22-316){ref-type="fig"}).

Association of *VEGF* SNPs with disease severity in RA
------------------------------------------------------

[Table 4](#t4-medscimonit-22-316){ref-type="table"} shows DAS28 stratified by the genotypes of the *VEGF* rs833070 and rs3025030 polymorphisms in all patients with RA. The mean DAS28 of all RA patients was 4.68±0.76, and RA patients were classified into low-activity RA patients (DAS28 ≤5.1) and high-activity RA patients (DAS28 \>5.1) according to DAS28 score system. Statistical difference was observed in DAS28 between different genotypes of *VEGF* rs833070 in RA patients (*P*\<0.05). RA patients carrying rs833070 AA genotype had a higher proportion of DAS28 \>5.1 compared with patients carrying rs833070 GG and AG genotype (100% *vs.* 33.3% *vs.* 56.8%). No statistical difference was detected in DAS28 between different genotypes of *VEGF* rs3025030 in RA patients (*P*\>0.05).

Synovial lesions in RA
----------------------

As seen in [Table 5](#t5-medscimonit-22-316){ref-type="table"}, among the 98 RA patients, synovial thickening was detected in 82 patients and in a total of 1,065 joints, with a positive rate of 38.8% (1065/2744). Joint effusion was observed in 90 patients and 747 joints, with a positive rate of 27.2% (747/2744). Doppler signal in 63 patients and 661 joints (excessive blood vessel formation), showed a positive rate of 24.1% (661/2744).

Association of *VEGF* SNPs with synovial lesions in RA
------------------------------------------------------

As illustrated in [Table 6](#t6-medscimonit-22-316){ref-type="table"}, there was statistical significance in the positive rate of synovial thickening, joint effusion and synovial angiogenesis between different genotypes of *VEGF* rs833070 and rs3025030 (*P*\<0.05). The positive rate of synovial thickening, joint effusion and synovial angiogenesis in RA patients carrying rs833070 AG and AA genotype was evidently higher than patients carrying rs833070 GG genotype (*P*\<0.05). Similarly, the positive rate of synovial thickening, joint effusion and synovial angiogenesis in RA patients with rs3025030 GC and GG genotype was higher compared to RA patients with rs3025030 CC genotype (*P*\<0.05).

Discussion
==========

In the current study, we investigated the significance of 2 SNPs in *VEGF* gene, rs833070 and rs3025030, which alter VEGF protein levels in the serum. The association of these *VEGF* gene variations with circulating serum levels of VEGF, disease activity, and synovial lesions was systematically measured in RA patients. Additionally, we carried out genotyping in a hospital-based case-control study in a cohort of 98 RA patients and 100 controls to obtain a comprehensive view of the disease parameters in relation to the genotypes under study.

The results of the SNP genotyping and ELISA based measurement of serum VEGF revealed that *VEGF* rs833070 AA genotype is related to higher serum VEGF level, and the same genotype and haplotype also occurred more frequently in RA patients. The GG genotype of *VEGF* rs3025030 was associated with a lower VEGF serum level, and the same genotype and haplotype showed a lower frequency in patients with RA, suggesting that *VEGF* rs833070 genetic polymorphisms is a significant risk factor in RA, while rs3025030 mutation in the *VEGF* gene might play a protective role in RA through lowering VEGF levels in serum. Previous studies have also reported enhanced serum VEGF levels in RA patients; however, the links to *VEGF* genetic variations as a mechanism to regulate serum VEGF levels, and leading to an increased or decreased risk of RA, are still unclear \[[@b10-medscimonit-22-316],[@b18-medscimonit-22-316]\]. It is hypothesized that *VEGF* polymorphisms influence *VEGF* gene transcription, resulting in altered serum levels of VEGF \[[@b5-medscimonit-22-316]\]. Although only a small change is observed in the absolute values of serum VEGF levels due to *VEGF* genetic polymorphisms, the disease outcomes show large differences and probably reflect a sustained activation of mechanisms promoting RA \[[@b19-medscimonit-22-316]\]. RA mainly results from pannus formation caused by synovial angiogenesis \[[@b20-medscimonit-22-316]\]. Furthermore, VEGF protein, one of the most potent inducers of angiogenesis, plays a vital role in activating angiogenesis in RA through up-regulation of the VEGF pathway \[[@b6-medscimonit-22-316]\]. Therefore, it is plausible to conclude that *VEGF* rs833070 polymorphism increases serum VEGF levels, and the higher VEGF serum levels confer increased risk of RA. On the other hand, *VEGF* rs3025030 polymorphism reduces VEGF protein levels in serum and decreases the onset of RA. Consistent with our observation, Ozgonenel et al. also demonstrated that higher VEGF levels are correlated to late phase and high risk of RA, independent of age and sex \[[@b10-medscimonit-22-316]\]. Moreover, Chen et al., who studied a sample of 413 hospital-based RA patients of Caucasian origin, reported that the T allele at *VEGF* rs3025039 could influence the onset of RA \[[@b21-medscimonit-22-316]\]. Additionally, a previous meta-analysis, which studied a total of 24 independent studies associated with autoimmune disease, revealed that *VEGF* polymorphisms were related to the susceptibility to RA \[[@b22-medscimonit-22-316]\].

In addition, the findings from our study show that rs833070 AA genotype in the *VEGF* gene was closely associated with high disease activity in RA, and both rs833070 and rs3025030 variants in the *VEGF* gene were positively associated with synovial thickening, joint effusion, and synovial angiogenesis, indicating that *VEGF* genetic polymorphisms might play roles in promoting disease activity, synovial thickening, joint effusion, and synovial angiogenesis in RA. Serum VEGF levels were positively correlated to ESR, RF, and CRP, which are independent variables for disease activity \[[@b23-medscimonit-22-316]\]. In addition, higher VEGF in serum might increase vascular permeability, which in turn contributes to joint effusion and joint swelling, which is related to the synovial thickening seen in RA \[[@b24-medscimonit-22-316]\]. As serum VEGF level rises, the number of swollen and sensitive joints, which is one of the DAS28 calculation parameters, rises as expected, contributing to high DASs \[[@b25-medscimonit-22-316]\]. The synovial angiogenesis in RA might be explained by the role of VEGF in angiogenesis \[[@b26-medscimonit-22-316]\]. A previous study showed that VEGF plays a central role in RA-related joint destruction, as evidenced by the observed radiologic changes and increased DAS in patients with high serum VEGF levels \[[@b27-medscimonit-22-316]\]. As well, Ozgonenel et al. reported that higher VEGF levels are associated with late phase and high disease activity in RA, independent of age and sex \[[@b9-medscimonit-22-316]\]. Chen et al. also have documented that genetic variation in the *VEGF* gene is associated with serum VEGF levels in RA, and shows an association with disease activity in RA patients who have never smoked, independent of serum VEGF levels \[[@b10-medscimonit-22-316]\]. One limitations of our study is that this was a hospital-based case-control study, hence the subjects were not representative of general population; nevertheless, this case-control study still had the ability to contribute to relatively reliable results. Another limitation is that the polymorphisms were evaluated based on their function, and may not supply a comprehensive view of the genetic variability of *VEGF*; therefore, further fine-mapping studies are needed. In addition, the sample size of this study was too small to investigate the low penetrance effect of the SNPs.

Conclusions
===========

Our study shows that variants in the *VEGF* gene might serve as biomarkers for disease activity and synovial lesions in RA, and are a useful biochemical parameter to assess the treatment effectiveness in RA.
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###### 

Primer sequence and primer length (bp) of rs833070 (G/A) and rs3025030 (G/C) in the *vascular endothelial growth factor* gene.

  SNP                                    Primers                                Primer length (bp)
  -------------------------------------- -------------------------------------- --------------------
  rs833070 (G/A)                         5′-ACGTTGGATGAAGTTCACAGCACCCGAACA-3′   86
  5′-ACGTTGGATGCCCTGGTTTGCATTCCTTTG-3′                                          
  rs3025030 (G/C)                        5′-ACGTTGGATGAAAATGTGTGGGCTGCTTGG-3′   111
  5′-ACGTTGGATGACACACTGAAGGAGCTGTAG-3′                                          

###### 

Comparison between demographic and clinical characteristics of patients with rheumatoid arthritis and demographic features of healthy controls.

  Variable               Control group (n=100)   RA group (n=98)   *P*
  ---------------------- ----------------------- ----------------- ---------
  Age (years)            48.67±13.41             50.82±12.53       0.245
  Gender (male/female)   35/65                   32/66             0.727
  WBC (×10^9^/L)         6.31±1.88               6.81±2.88         0.114
  RBC (×10/L)            4.69±0.31               4.64±0.66         0.498
  PLT (×10/L)            276.6±64.5              282.55±65.9       0.521
  HGB (g/L)              129.6±12.0              127.0±11.9        0.125
  ESR (mm/h)             16.31±2.75              36.39±3.44        \<0.001
  CRP (mg/L)             2.01±0.37               13.36±4.72        \<0.001
  RF (IU/mL)             12.18±1.72              43.58±3.53        \<0.001
  VEGF (pg/mL)           307.30±119.52           1436.44±423.41    \<0.001

Values are means ± standard deviation or number; RA -- rheumatoid arthritis; WBC -- white blood cell; RBC -- red blood cell; PLT -- platelet; HGB -- hemoglobin; ESR -- erythrocyte sedimentation rate; CRP -- C-reactive protein; RF -- rheumatoid factor; VEGF -- vascular endothelial growth factor.

###### 

Comparison of distribution of genotype and allele frequencies of *vascular endothelial growth factor* rs833070 (G\>A) and rs3025030 (G\>C) polymorphisms between rheumatoid arthritis patients (n=98) and controls (n=100).

  SNP         RA group (n=98)   Control group (n=100)   P       OR      95%CI
  ----------- ----------------- ----------------------- ------- ------- --------------
  rs833070                                                              
   GG         3 (3.1%)          9 (9.0%)                                
   AG         37 (37.8%)        48 (48.0%)              0.036           
   AA         58 (59.2%)        43 (43.0%)                              
   GG + AG    40 (40.8%)        57 (57.0%)              Ref             
   AA         58 (59.2%)        43 (3.0%)               0.023   1.922   1.093--3.382
   AG + AA    95 (96.9%)        91 (91.0%)              Ref             
   GG         3 (3.1%)          9 (9.0%)                0.080   0.319   0.084--1.217
   G allele   43 (21.9%)        66 (33.0%)                      1.000   
   A allele   153 (78.1%)       134 (67.0%)             0.014   1.753   1.119--2.745
  rs3025030                                                             
   CC         48 (50.0%)        67 (67.0%)                              
   GC         40 (40.8%)        28 (28.0%)              0.032           
   GG         10 (10.2%)        5 (50.0%)                               
   GC + CC    88 (89.8%)        95 (95.0%)              Ref             
   GG         40 (40.8%)        28 (28.0%)              0.167   2.159   0.710--6.566
   GC + GG    50 (51.0%)        33 (33.0%)              Ref             
   CC         40 (40.8%)        28 (28.0%)              0.010   0.473   0.266--0.840
   C          136 (69.4%)       162 (81.0%)                     1.00    
   G          60 (30.6%)        38 (19.0%)              0.007   1.881   1.180--2.997

SNP -- single-nucleotide polymorphism; RA -- rheumatoid arthritis; CI -- confidence interval; Ref -- reference.

###### 

Comparison of disease activity in rheumatoid arthritis between GG, AG, and AA genotype of rs833070, as well as between CC, GC, and GG genotype of rs3025030 in the *vascular endothelial growth factor* gene showing the relationship of *vascular endothelial growth factor* polymorphisms with disease activity in patients with rheumatoid arthritis.

              DAS28 (n,%)   *P*
  ----------- ------------- ------------
  rs833070    \<0.0001      
   GG         2 (66.7%)     1 (33.3%)
   AG         16 (43.2%)    21 (56.8%)
   AA         0 (0.0%)      58 (100%)
  rs3025030   0.773         
   CC         10 (100%)     38 (0.0%)
   GC         6 (72.5%)     34 (27.5%)
   GG         2 (10.0%)     8 (90.0%)

DAS28 -- 28-joint disease activity score.

###### 

Positive rate of synovial thickening, joint effusion and synovial angiogenesis \[number of joints (%)\] detected by high-resolution ultrasound and Doppler ultrasound.

  Joint                                          No. of examined joints   Joints with synovial thickening   Joints with joint effusion   Joints with excessive synovial angiogenesis
  ---------------------------------------------- ------------------------ --------------------------------- ---------------------------- ---------------------------------------------
  Shoulders                                      196                      82 (41.8)                         65 (33.2)                    73 (37.2)
  Elbows                                         196                      102 (52.0)                        58 (29.6)                    79 (40.3)
  Wrists                                         196                      108 (55.1)                        69 (35.2)                    67 (34.2)
  Metacarpophalangeal joints                     980                      274 (30.0)                        209 (21.3)                   154 (15.7)
  Proximal interphalangeal joints of the hands   980                      351 (35.8)                        225 (33.0)                   175 (17.9)
  Knees                                          196                      148 (75.5)                        121 (61.7)                   113 (57.7)
  Total                                          2744                     1065 (38.8)                       747 (27.2)                   661 (24.1)

No. -- number.

###### 

Comparison of synovial lesions in rheumatoid arthritis between GG, AG, and AA genotype of rs833070, as well as between CC, GC, and GG genotype of rs3025030 in the *vascular endothelial growth factor* gene showing the relationship of *vascular endothelial growth factor* polymorphisms with synovial lesions in patients with rheumatoid arthritis.

              Joints with synovial thickening                                 Joints with joint effusion                                      Joints with excessive synovial angiogenesis
  ----------- --------------------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------
  rs833070                                                                                                                                    
   GG         20 (23.8)                                                       12 (14.3)                                                       5 (6.0)
   AG         385 (37.2)[\*](#tfn5-medscimonit-22-316){ref-type="table-fn"}   250 (24.1)[\*](#tfn5-medscimonit-22-316){ref-type="table-fn"}   214 (20.7)[\*](#tfn5-medscimonit-22-316){ref-type="table-fn"}
   AA         653 (40.2)[\*](#tfn5-medscimonit-22-316){ref-type="table-fn"}   489 (30.1)[\*](#tfn5-medscimonit-22-316){ref-type="table-fn"}   442 (27.2)[\*](#tfn5-medscimonit-22-316){ref-type="table-fn"}
  rs3025030                                                                                                                                   
   CC         479 (35.6)                                                      253 (18.6)                                                      114 (6.7)
   GC         460 (41.1)[\#](#tfn6-medscimonit-22-316){ref-type="table-fn"}   310 (30.7)[\#](#tfn6-medscimonit-22-316){ref-type="table-fn"}   413 (42.2)[\#](#tfn6-medscimonit-22-316){ref-type="table-fn"}
   GG         126 (45.0)[\#](#tfn6-medscimonit-22-316){ref-type="table-fn"}   184 (72.5)[\#](#tfn6-medscimonit-22-316){ref-type="table-fn"}   134 (57.5)[\#](#tfn6-medscimonit-22-316){ref-type="table-fn"}

Compared with GG genotype, *P*\<0.05;

compared with CC genotype, *P*\<0.05.

[^1]: Study Design

[^2]: Data Collection

[^3]: Statistical Analysis

[^4]: Data Interpretation

[^5]: Manuscript Preparation

[^6]: Literature Search

[^7]: Funds Collection
